β-Secretases, Alzheimer's Disease, and Down Syndrome

Overview

Journal Curr Gerontol Geriatr Res

Specialty Geriatrics

Date 2012 Apr 7

PMID 22481915

Citations 13

Authors

Robin L Webb

M Paul Murphy

Affiliations

Soon will be listed here.

Abstract

Individuals with Down Syndrome (DS), or trisomy 21, develop Alzheimer's disease (AD) pathology by approximately 40 years of age. Chromosome 21 harbors several genes implicated in AD, including the amyloid precursor protein and one homologue of the β-site APP cleaving enzyme, BACE2. Processing of the amyloid precursor protein by β-secretase (BACE) is the rate-limiting step in the production of the pathogenic Aβ peptide. Increased amounts of APP in the DS brain result in increased amounts of Aβ and extracellular plaque formation beginning early in life. BACE dysregulation potentially represents an overlapping biological mechanism with sporadic AD and a common therapeutic target. As the lifespan for those with DS continues to increase, age-related concerns such as obesity, depression, and AD are of growing concern. The ability to prevent or delay the progression of neurodegenerative diseases will promote healthy aging and improve quality of life for those with DS.

Citing Articles

An empirical bayesian approach for testing gene expression fold change and its application in detecting global dosage effects.

Guo Z, Cui Y, Shi X, Birchler J, Albizua I, Sherman S NAR Genom Bioinform. 2021; 2(3):lqaa072.

PMID: 33575620 PMC: 7671412. DOI: 10.1093/nargab/lqaa072.

Down syndrome and Alzheimer's disease: common molecular traits beyond the amyloid precursor protein.

Gomez W, Morales R, Maracaja-Coutinho V, Parra V, Nassif M Aging (Albany NY). 2020; 12(1):1011-1033.

PMID: 31918411 PMC: 6977673. DOI: 10.18632/aging.102677.

Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome.

Tramutola A, Lanzillotta C, Barone E, Arena A, Zuliani I, Mosca L Transl Neurodegener. 2018; 7:28.

PMID: 30410750 PMC: 6218962. DOI: 10.1186/s40035-018-0133-9.

Can Animal Models Inform on the Relationship between Depression and Alzheimer Disease?.

Nyarko J, Quartey M, Baker G, Mousseau D Can J Psychiatry. 2018; 64(1):18-29.

PMID: 29685068 PMC: 6364140. DOI: 10.1177/0706743718772514.

When nature's robots go rogue: exploring protein homeostasis dysfunction and the implications for understanding human aging disease pathologies.

Reisz J, Barrett A, Nemkov T, Hansen K, DAlessandro A Expert Rev Proteomics. 2018; 15(4):293-309.

PMID: 29540077 PMC: 6174679. DOI: 10.1080/14789450.2018.1453362.

References

Sinha S, Anderson J, Barbour R, Basi G, Caccavello R, Davis D . Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature. 1999; 402(6761):537-40. DOI: 10.1038/990114. View

Abbott A . Dementia: a problem for our age. Nature. 2011; 475(7355):S2-4. DOI: 10.1038/475S2a. View

Fukumoto H, Cheung B, Hyman B, Irizarry M . Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol. 2002; 59(9):1381-9. DOI: 10.1001/archneur.59.9.1381. View

Cummings B, Satou T, Head E, Milgram N, Cole G, Savage M . Diffuse plaques contain C-terminal A beta 42 and not A beta 40: evidence from cats and dogs. Neurobiol Aging. 1996; 17(4):653-9. DOI: 10.1016/0197-4580(96)00062-0. View

Barbiero L, Benussi L, Ghidoni R, Alberici A, Russo C, Schettini G . BACE-2 is overexpressed in Down's syndrome. Exp Neurol. 2003; 182(2):335-45. DOI: 10.1016/s0014-4886(03)00049-9. View

Price J, McKeel Jr D, Buckles V, Roe C, Xiong C, Grundman M . Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009; 30(7):1026-36. PMC: 2737680. DOI: 10.1016/j.neurobiolaging.2009.04.002. View

Devenny D, Krinsky-McHale S, Sersen G, Silverman W . Sequence of cognitive decline in dementia in adults with Down's syndrome. J Intellect Disabil Res. 2000; 44 ( Pt 6):654-65. DOI: 10.1046/j.1365-2788.2000.00305.x. View

Yan R, Bienkowski M, Shuck M, Miao H, Tory M, Pauley A . Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature. 1999; 402(6761):533-7. DOI: 10.1038/990107. View

Braak H, Braak E . Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239-59. DOI: 10.1007/BF00308809. View

10.

Hussain I, Powell D, Howlett D, Tew D, Meek T, Chapman C . Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci. 1999; 14(6):419-27. DOI: 10.1006/mcne.1999.0811. View

11.

Rasmussen S, Whitehead N, Collier S, Frias J . Setting a public health research agenda for Down syndrome: summary of a meeting sponsored by the Centers for Disease Control and Prevention and the National Down Syndrome Society. Am J Med Genet A. 2008; 146A(23):2998-3010. DOI: 10.1002/ajmg.a.32581. View

12.

Salomone S, Caraci F, Leggio G, Fedotova J, Drago F . New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol. 2011; 73(4):504-17. PMC: 3376428. DOI: 10.1111/j.1365-2125.2011.04134.x. View

13.

Vassar R, Bennett B, Kahn S, Mendiaz E, Denis P, Teplow D . Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999; 286(5440):735-41. DOI: 10.1126/science.286.5440.735. View

14.

Masliah E, Mallory M, Hansen L, DeTeresa R, Alford M, Terry R . Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci Lett. 1994; 174(1):67-72. DOI: 10.1016/0304-3940(94)90121-x. View

15.

Allen E, Freeman S, Druschel C, Hobbs C, OLeary L, Romitti P . Maternal age and risk for trisomy 21 assessed by the origin of chromosome nondisjunction: a report from the Atlanta and National Down Syndrome Projects. Hum Genet. 2008; 125(1):41-52. PMC: 2833410. DOI: 10.1007/s00439-008-0603-8. View

16.

Kang J, Lemaire H, Unterbeck A, Salbaum J, Masters C, Grzeschik K . The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987; 325(6106):733-6. DOI: 10.1038/325733a0. View

17.

Miners J, Morris S, Love S, Kehoe P . Accumulation of insoluble amyloid-β in down's syndrome is associated with increased BACE-1 and neprilysin activities. J Alzheimers Dis. 2010; 23(1):101-8. DOI: 10.3233/JAD-2010-101395. View

18.

Selkoe D . Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci. 1994; 17:489-517. DOI: 10.1146/annurev.ne.17.030194.002421. View

19.

Suzuki N, Cheung T, Cai X, Odaka A, Otvos Jr L, Eckman C . An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 1994; 264(5163):1336-40. DOI: 10.1126/science.8191290. View

20.

Cheon M, Dierssen M, Kim S, Lubec G . Protein expression of BACE1, BACE2 and APP in Down syndrome brains. Amino Acids. 2007; 35(2):339-43. DOI: 10.1007/s00726-007-0618-9. View